Medco regulatory update

The FDA issued a non-approvable letter for MRE’s ViaScint (123I-Iodophenylpentadeconoic acid), a radiopharmaceutical designed

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE